Endoscopic duodenal-jejunal bypass liner may significantly improve glycemic control and weight loss in patients with poorly controlled type 2 diabetes and obesity.

• At one year, HbA1c levels dropped by 1.10% in the DJBL group, compared to just 0.28% in the sham group (p=0.0004).
• Patients with HbA1c ≤ 7% more than tripled in the DJBL group (28.3% vs. 9.4%, p=0.0003).

Consider DJBL for selected patients as it may enhance weight loss and glycemic outcomes.

• Device-related serious adverse event rate was 9.4%, with specific concerns being intolerance (3.7%) and hemorrhage (2.8%).